Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705)

Michinori Ogura, Kuniaki Itoh, Kenichi Ishizawa, Yukio Kobayashi, Kensei Tobinai, Tomohiro Kinoshita, Masami Hirano, Ryuzo Ueda, Taro Shibata, Shigeo Nakamura, Kunihiro Tsukasaki, Tomomitsu Hotta, Masanori Shimoyama, Yasuo Morishima

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    The role of dacarbazine in ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) therapy in Hodgkin lymphoma (HL) remains unclear. This phase II study assessed the efficacy and safety of ABV therapy with an increased doxorubicin dose (30 mg/m2) in advanced-stage HL. The primary endpoint was complete response rate (%CR). Patients received six or eight cycles of ABV every 4 weeks followed by involved-field radiation therapy (IFRT) in residual disease and initial bulky mass. Seventy-two patients were enrolled. An interim analysis in 46 assessable patients showed that %CR had exceeded the stopping criteria.However, the 2-year progression-free survival (%PFS) rate of 49.4% (95% confidence interval [CI] 32.2-66.6) was markedly lower than the 79.2% PFS (95% CI 70.6-87.7) seen in our previously reported study (JCOG9305) of ABVd with two-thirds the dose of dacarbazine of the original ABVD. Therefore, the study was closed early. The %CR in the 70 eligible patients after ABV was 31.4% (95% CI 20.9-43.6) and was increased to 70.0% (95% CI 57.9-80.4) after the addition of IFRT. ABV was inferior to ABVd for PFS in patients with advanced HL, suggesting that dacarbazine is indispensable in ABVD/ABVd.

    Original languageEnglish
    Pages (from-to)46-52
    Number of pages7
    JournalLeukemia and Lymphoma
    Volume54
    Issue number1
    DOIs
    Publication statusPublished - 2013 Jan

    Keywords

    • ABV therapy followed by IFRT
    • First-line chemotherapy
    • Hodgkin lymphoma
    • Phase II study

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705)'. Together they form a unique fingerprint.

  • Cite this

    Ogura, M., Itoh, K., Ishizawa, K., Kobayashi, Y., Tobinai, K., Kinoshita, T., Hirano, M., Ueda, R., Shibata, T., Nakamura, S., Tsukasaki, K., Hotta, T., Shimoyama, M., & Morishima, Y. (2013). Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705). Leukemia and Lymphoma, 54(1), 46-52. https://doi.org/10.3109/10428194.2012.705000